Structural analysis of CYP2C9 and CYP2C5 and an evaluation of commonly used molecular modeling techniques

被引:19
作者
Afzelius, L [1 ]
Raubacher, F
Karlén, A
Jorgensen, FS
Andersson, TB
Masimirembwa, CM
Zamora, I
机构
[1] AstraZeneca R&D, Dept Drug Metab & Pharmacokinet & Bioanalyt Chem, S-43183 Molndal, Sweden
[2] AstraZeneca R&D, Dept Med Chem, Molndal, Sweden
[3] Uppsala Univ, Dept Organ Pharmaceut Chem, Uppsala, Sweden
[4] Lead Mol Design, Barcelona, Spain
[5] Inst Municipal Invest Med, E-08003 Barcelona, Spain
[6] Danish Univ Pharmaceut Sci, Copenhagen, Denmark
关键词
D O I
10.1124/dmd.32.11.1218
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This work had two separate aims: to evaluate different modeling techniques and to make a detailed structural characterization of CYP2C9. To achieve these goals, the consensus principal component analysis ( CPCA) technique and distance measurements were used to explore available crystal structures, newly built homology models, and repeated molecular dynamics simulations. The CPCA was based on molecular interaction fields focused on the active site regions of the proteins and include detailed amino acid analysis. The comparison of the CYP2C9 and CYP2C5 crystal structures revealed differences in the flexible regions such as the B-C and F-G loop and the N and C termini. Cross homology models of CYP2C9 and CYP2C5, using their respective crystal structures as templates, indicated that such models were more similar to their templates than to their target proteins. Inclusion of multiple templates slightly improved the similarity to the crystal target in some cases and could be recommended even though it requires a careful manual alignment process. The application of molecular dynamics simulations to highly flexible proteins such as cytochromes P450 is also explored and the information is extracted by the CPCA. Advantages and drawbacks are presented for the different modeling techniques. Despite the varying modeling success, the models give insight and understanding by the mutual forming and discarding of hypotheses. This is a dynamic process since the crystal structures are improving with time and, therefore, the answers to the models are also changing accordingly.
引用
收藏
页码:1218 / 1229
页数:12
相关论文
共 39 条
[1]   Competitive CYP2C9 inhibitors:: Enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis [J].
Afzelius, L ;
Zamora, I ;
Ridderström, M ;
Andersson, TB ;
Karlén, A ;
Masimirembwa, CM .
MOLECULAR PHARMACOLOGY, 2001, 59 (04) :909-919
[2]   GENERATING OPTIMAL LINEAR PLS ESTIMATIONS (GOLPE) - AN ADVANCED CHEMOMETRIC TOOL FOR HANDLING 3D-QSAR PROBLEMS [J].
BARONI, M ;
COSTANTINO, G ;
CRUCIANI, G ;
RIGANELLI, D ;
VALIGI, R ;
CLEMENTI, S .
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS, 1993, 12 (01) :9-20
[3]   MOLECULAR-DYNAMICS WITH COUPLING TO AN EXTERNAL BATH [J].
BERENDSEN, HJC ;
POSTMA, JPM ;
VANGUNSTEREN, WF ;
DINOLA, A ;
HAAK, JR .
JOURNAL OF CHEMICAL PHYSICS, 1984, 81 (08) :3684-3690
[4]  
CASE DA, AMBER 7
[5]   A 2ND GENERATION FORCE-FIELD FOR THE SIMULATION OF PROTEINS, NUCLEIC-ACIDS, AND ORGANIC-MOLECULES [J].
CORNELL, WD ;
CIEPLAK, P ;
BAYLY, CI ;
GOULD, IR ;
MERZ, KM ;
FERGUSON, DM ;
SPELLMEYER, DC ;
FOX, T ;
CALDWELL, JW ;
KOLLMAN, PA .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1995, 117 (19) :5179-5197
[6]   Crystal structures of ligand complexes of P450eryF exhibiting homotropic cooperativity [J].
Cupp-Vickery, J ;
Anderson, R ;
Hatziris, Z .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) :3050-3055
[7]   Molecular modeling of mammalian cytochrome P450s [J].
Dai, R ;
Pincus, MR ;
Friedman, FK .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (03) :487-499
[8]   Assessment of arginine 97 and lysine 72 as determinants of substrate specificity in cytochrome P4502C9 (CYP2C9) [J].
Davies, C ;
Witham, K ;
Scott, JR ;
Pearson, A ;
DeVoss, JJ ;
Graham, SE ;
Gillam, EMJ .
DRUG METABOLISM AND DISPOSITION, 2004, 32 (04) :431-436
[9]   Development of a combined protein and pharmacophore model for cytochrome P4502C9 [J].
de Groot, MJ ;
Alex, AA ;
Jones, BC .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (10) :1983-1993
[10]   Oxidizing species in the mechanism of cytochrome P450 [J].
de Montellano, PRO ;
De Voss, JJ .
NATURAL PRODUCT REPORTS, 2002, 19 (04) :477-493